Biography
Dr. Andrew Nierenberg is Medical Director of the Bipolar Clinic and Research Program and Associate Director of the Depression Clinical and Research Program at Massachusetts General Hospital. Dr. Nierenberg is Professor of Psychiatry at Harvard Medical School.
Dr. Nierenberg is a graduate of the Albert Einstein College of Medicine of Yeshiva University, Bronx, New York. He completed his residency in psychiatry at New York University / Bellevue Hospital in New York City. He next studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar. Dr Nierenberg continued his trek north to join the faculty at Harvard Medical School, first to direct one of the Affective Disorders Inpatient Units and then to direct the Affective Disorders Outpatient Unit at McLean Hospital in Belmont, Massachusetts. He then joined the Department of Psychiatry at Massachusetts General Hospital in 1992, where he holds his current positions.
Dr. Nierenberg has published over 200 original articles and has been listed in The Best Doctors In America for the treatment of mood and anxiety disorders in every edition since 1994. In 2000, he was awarded the Gerald L. Klerman Young Investigator award by the National Depression and Manic-Depressive Association (NDMDA) and two independent Investigator Awards by the National Association for Research in Schizophrenia and Depression (NARSAD). Dr. Nierenberg was elected as a member of the American College of Neuropsychopharmacology in 2005.
Dr. Nierenberg was on the leadership teams of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) and the Sequential Treatment Alternatives to Relieve Depression (STAR*D) National Institute of Mental Health (NIMH) contracts, two unprecedented clinical trials that included thousands of patients with mood disorders. Since October 2005, he has been the PI and Director of the NIMH Bipolar Trials Network.
Dr. Nierenberg’s primary interests are treatment-resistant depression, bipolar depression, juvenile bipolar disorder, and the longitudinal course of affective disorders. He lectures extensively, both nationally and internationally, teaches, maintains an active clinical practice, conducts clinical trials funded by the NIMH and industry, was a member of the NIMH Initial Review Group for Intervention Research and serves as a peer reviewer for over 25 psychiatric journals. He is a member of the editorial board of the Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, International Journal of Neuropsychopharmacology, and Bipolar Disorders.
Disclosure
Research Support
Pfizer and NIMH.
Advisory/Consulting
Astra-Zeneca, BrainCells Inc, Eli Lilly & Co., Merck & Co., Jazz Pharmaceuticals, NIMH, Novartis, Schering-Plough.
Last updated: 7/27/2010
Courses
Residual Symptoms of Depression: Lethargy and Cognitive Compromise
Major Depressive Disorder: Present State of Clinical Care, Assessing Treatment Challenges
Treatment Non-Adherence: Factors Disrupting Continuity of Care and Compromising Functional Recovery
Psychopharmacology Updates: A Comprehensive Review of Evidence-Based Approaches
Special Topics in Management of Major Depressive Disorder and Related Mood Disorders
Special Topics in Management of Major Depressive Disorder and Related Mood Disorders
Interactive Learning Module: Affective Disorders Diagnostic and Therapeutic Challenges